Edition:
United Kingdom

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (1349.HK)

1349.HK on Hong Kong Stock

3.28HKD
7:59am GMT
Change (% chg)

HK$-0.08 (-2.38%)
Prev Close
HK$3.36
Open
HK$3.36
Day's High
HK$3.36
Day's Low
HK$3.24
Volume
451,000
Avg. Vol
978,204
52-wk High
HK$6.80
52-wk Low
HK$3.17

Latest Key Developments (Source: Significant Developments)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ‍Expects To Record A Decrease In FY Net Profit
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd <1349.HK>::‍EXPECTS TO RECORD A DECREASE IN NET PROFIT OF GROUP BY APPROXIMATELY 50% FOR FY.‍EXPECTS DECREASE IN FY REVENUE OF GROUP BY APPROXIMATELY 20%.EXPECTED DECREASE IN REVENUE DUE TO DECREASED REVENUE FROM LIBOD BY ABOUT 50% FOR FY ENDED 31 DEC 2017​.  Full Article

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical subscribes for RMB60 mln in Shanghai BVCF's fund
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Shanghai Fudan-zhangjiang Bio-pharmaceutical Co Ltd <1349.HK>::Subscribed for RMB60 million in Shanghai BVCF's ‍BVCF fund.  Full Article

Shanghai Fudan-Zhangjiang Bio-Pharma enters into renewal agreement with Shanghai Pharma
Wednesday, 10 May 2017 

May 10 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co <1349.HK>:Company and shanghai pharmaceuticals entered into renewal agreement.Agreement for cooperation on innovative pharmaceuticals research & development for 3 years until 31 Dec 2019.  Full Article

Shanghai Fudan-Zhangjiang Bio-pharma unit obtained drug approval
Monday, 17 Oct 2016 

Shanghai Fudan-zhangjiang Bio-pharmaceutical Co Ltd <1349.HK>:Shanghai fudan-zhangjiang bio-pharmaceutical - unit as obtained drug approval issued by china fda for hemoporfin for injection.  Full Article